论文部分内容阅读
美罗华(利妥昔单抗注射液)联合CHOP化疗方案已成为CD20+B细胞非霍奇金淋瘤(B-NHL)的一线治疗标准。近年来与其应用相关的间质性肺炎(IP)发生越来越多,《中国肿瘤临床》2016年第7期刊登一篇来自天津医科大学肿瘤医院淋巴瘤科的大样本分析,探讨IP的发生与美罗华使用的关系及IP发生的危险因素。阅读本文请登录网站www.cjco.cn或关注本刊微信公告号(扫描文章下方二维码)查看。
Rituximab (Rituximab injection) combined with CHOP chemotherapy regimen has become the first-line treatment standard for CD20 + B cell non-Hodgkin’s lymphoma (B-NHL). In recent years, with its application more and more interstitial pneumonia (IP) occurred, “China Oncology” 2016 the seventh issue published a large sample from the Tianjin Medical University Cancer Hospital lymphoma large sample analysis of the occurrence of IP Relationship with Rituximab and risk factors for IP occurrence. Read this article, please visit www.cjco.cn or concerned about the publication of WeChat announcement (scan the article below the two-dimensional code) view.